NEW YORK (CNN) – High-risk patients with stable heart disease may only be successful with medications as a successful alternative to invasive heart surgery such as stents and bypass surgery, according to a large study. The findings were presented on Saturday at the annual American Heart Association conference.
While invasive procedures have been shown to improve chest pain and quality of life in some patients, some key findings did not differ significantly, including subsequent myocardial infarction, hospitalization for unstable chest pain or heart failure, cardiac arrest recovery, and death Cardiovascular causes.
"Do patients want to know if this treatment will let me live longer?" study leader Dr. Judith Hochman, Senior Associate Dean for Clinical Sciences at NYU Langone Health. "Based on what we saw, we did not see any evidence that they would live longer."
Stents and bypass operations are commonly used in patients with heart attacks, but whether in patients who are stable ̵
Patients with myocardial infarction were not included in the study, as were other groups, including patients with poor cardiac muscle function or patients with narrowing of the main coronary artery of the heart.
However, in patients with stable heart disease, we chose "patients with a very abnormal stress test," Hochman explained. "It has been suggested that patients who would benefit from an invasive strategy of stent or bypass surgery would benefit."
The international study launched in 2012 included more than 5,000 out of 37 patients. This is the largest study of its kind, the researchers said. Hochman said it builds on two earlier studies that draw similar conclusions, but in part do not find wide acceptance among physicians due to their design.
When asymptomatic patients renounce invasive therapies, Hochman estimates that hundreds of millions of dollars could be saved in the United States based on previous research.
"The impact is quite large worldwide and in the United States," she said.
The-CNN-Wire ™ & © 2018 Cable News Network, Inc., a Time Warner Company. All rights reserved.